Federation des caisses Desjardins du Quebec raised its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 1.9% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 992,585 shares of the pharmacy operator's stock after acquiring an additional 18,120 shares during the quarter. Federation des caisses Desjardins du Quebec owned approximately 0.08% of CVS Health worth $67,248,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the stock. Goldman Sachs Group Inc. increased its stake in CVS Health by 87.5% in the first quarter. Goldman Sachs Group Inc. now owns 9,927,650 shares of the pharmacy operator's stock valued at $672,598,000 after purchasing an additional 4,632,530 shares during the last quarter. Dodge & Cox increased its stake in CVS Health by 4.8% in the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator's stock valued at $4,976,856,000 after purchasing an additional 3,353,223 shares during the last quarter. Nuveen LLC acquired a new position in CVS Health in the first quarter valued at $204,421,000. Fairfax Financial Holdings Ltd. Can acquired a new position in CVS Health in the fourth quarter valued at $121,742,000. Finally, Assenagon Asset Management S.A. increased its stake in CVS Health by 310.8% in the first quarter. Assenagon Asset Management S.A. now owns 3,523,824 shares of the pharmacy operator's stock valued at $238,739,000 after purchasing an additional 2,666,029 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.
CVS Health Stock Up 0.1%
Shares of NYSE CVS traded up $0.07 on Friday, hitting $73.76. The company had a trading volume of 5,074,859 shares, compared to its average volume of 5,804,935. CVS Health Corporation has a 12-month low of $43.56 and a 12-month high of $74.53. The business has a 50 day moving average of $66.60 and a two-hundred day moving average of $66.00. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $93.56 billion, a P/E ratio of 20.60, a PEG ratio of 0.81 and a beta of 0.62.
CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.35. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The company had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. During the same quarter in the prior year, the business earned $1.83 earnings per share. The company's revenue was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.
CVS Health Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Tuesday, July 22nd were given a $0.665 dividend. The ex-dividend date of this dividend was Tuesday, July 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.6%. CVS Health's dividend payout ratio is presently 74.30%.
Insider Buying and Selling at CVS Health
In other news, Director Anne A. Finucane sold 7,500 shares of the company's stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the sale, the director owned 22,156 shares of the company's stock, valued at $1,573,519.12. This represents a 25.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.22% of the stock is owned by insiders.
Analyst Ratings Changes
CVS has been the subject of several analyst reports. Baird R W upgraded CVS Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Wall Street Zen upgraded CVS Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Jefferies Financial Group boosted their price target on CVS Health from $74.00 to $80.00 and gave the company a "buy" rating in a research report on Monday, June 30th. Bernstein Bank lowered their price target on CVS Health from $78.00 to $72.00 and set a "market perform" rating for the company in a research report on Wednesday, July 16th. Finally, Truist Financial boosted their price target on CVS Health from $82.00 to $84.00 and gave the company a "buy" rating in a research report on Monday, May 12th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $77.89.
View Our Latest Report on CVS
CVS Health Company Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Further Reading

Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.